In Monday trade, Glenmark Pharma shares saw a spout of 35 per cent after announcing launching an antiviral drug Favipiravir, under FabiFlu brand name on Saturday to treat mild to moderate Covid-19 patients at Rs. 103 per tablet.
The company said in a regulatory filing,” The drugs would come in a strip of 34 tablets with a dose of 200 mg Favipiravir per tablet at the maximum retail price of Rs 3,500. FabiFlu is an oral approved treatment of Covid-19 in India.
Glenmark Pharma also said that this was the first oral approved medication launched to treat coronavirus patients in India.
What is the Recommended Medical Prescription?
It is a prescribed medication with recommended 1800 mg twice dose on one day, followed by 800 mg twice from 2 nds of day to 14 days.
The Mumbai based drug firm received the approval of manufacturing and marketing from the Drugs Controller General of India (DCGI) on Friday.
Officials Statement: Glenmark Pharma
Glenmark also said,” Favipiravir would be effective for Covid-19 patients with co-morbid conditions like diabetes and heart disease with mild to moderate coronavirus symptoms.”
“Favipiravir claims viral load reduction within four days and rapid symptomatic and radiological improvement. It has recorded a clinical improvement in mild to moderate Covid-19 cases by up to 88 per cent”, it said.
Glenmark pharma ltd. also informed BSE about the upcoming meeting sharing the success rate of prescribed medication among the Covid-19 patients.
On Monday, the Glenmark Pharmaceutical shares closed at a 27.06 per cent high at Rs 519.80 on BSE, making it the biggest intraday rise in the history of trading.
Table of Contents